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Comparison of risk factor associations in UK Biobank against 
representative, general population based studies with  
conventional response rates: prospective cohort study and  
individual participant meta-analysis
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AbstrAct
Objective
To compare established associations between risk 
factors and mortality in UK Biobank, a study with an 
exceptionally low rate of response to its baseline 
survey, against those from representative studies that 
have conventional response rates.
Design
Prospective cohort study alongside individual 
participant meta-analysis of other cohort studies.
setting
United Kingdom.
ParticiPants
Analytical sample of 499 701 people (response 
rate 5.5%) in analyses in UK Biobank; pooled data 
from the Health Surveys for England (HSE) and the 
Scottish Health Surveys (SHS), including 18 studies 
and 89 895 people (mean response rate 68%). Both 
study populations were linked to the same nationwide 
mortality registries, and the baseline age range was 
aligned at 40-69 years.
Main OutcOMe Measure
Death from cardiovascular disease, selected 
malignancies, and suicide. To quantify the difference 
between hazard ratios in the two studies, a ratio of the 
hazard ratios was used with HSE-SHS as the referent.
results
Risk factor levels and mortality rates were typically 
more favourable in UK Biobank participants relative 
to the HSE-SHS consortium. For the associations 
between risk factors and mortality endpoints, 
however, close agreement was seen between studies. 
Based on 14 288 deaths during an average of 7.0 
years of follow-up in UK Biobank and 7861 deaths 
over 10 years of mortality surveillance in HSE-SHS, for 
cardiovascular disease mortality, for instance, the age 
and sex adjusted hazard ratio for ever having smoked 
cigarettes (versus never) was 2.04 (95% confidence 
interval 1.87 to 2.24) in UK Biobank and 1.99 (1.78 
to 2.23) in HSE-SHS, yielding a ratio of hazard ratios 
close to unity (1.02, 0.88 to 1.19). The overall pattern 
of agreement between studies was essentially 
unchanged when results were compared separately 
by sex and when baseline years and censoring dates 
were aligned.
cOnclusiOn
Despite a very low response rate, risk factor 
associations in the UK Biobank seem to be 
generalisable.
Introduction
Well designed prospective cohort studies have 
considerable utility in identifying genetic and environ­
mental risk factors for an array of somatic and 
psychiatric disorders. In the many contexts in which 
randomised controlled trials are not feasible owing to 
financial, ethical, or logistical constraints, this type of 
observational study provides the best approximation 
of causality. Although well phenotyped cohort stu­
dies have existed for decades, recent technological 
advances have led to low cost, high throughput 
methods to quantify genetic variation. Simultaneously 
expanding prospects for linkage to medical and non­
medical electronic records has allowed construction of 
studies with the capacity to explore the effect of gene­
environment combinations on health endpoints at a 
previously unheralded scale. Several countries have 
established such national “biobanks,”1 2 are in the 
process of their formulation,3­5 or are planning such an 
endeavour.6
One such leading resource is UK Biobank, a 
prospective cohort study comprising around 500 000 
middle aged and older people.7 Unusually in the 
context of medical research, baseline data have 
been open access since completion of curation in 
2012,8 and, to date, the study has yielded in excess 
of 1000 publications.9 Although UK Biobank is rare 
in its combination of size and content, it also had an 
uncommonly low response to its baseline survey: of 
more than nine million people sent an invitation to 
participate, only around 6% did so.10 This achieved 
response rate was driven by the cost and time saving 
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WhAt Is AlreAdy knoWn on thIs topIc
The primary objective of UK Biobank is to identify risk factors for chronic diseases 
and injuries of public health importance
That the baseline response rate was an order of magnitude lower than is 
conventional has led to debate as to the generalisability of its findings
Relative to studies with higher response rates and national statistics, baseline 
risk factor profile and mortality rates in UK Biobank are more favourable, but the 
impact, if any, on risk factor associations is unknown
WhAt thIs study Adds
This is the first study to directly compare risk factor associations in UK Biobank 
with nationally representative cohort studies with conventional response rates
Associations of a wide range of risk factors with mortality outcomes showed 
close agreement between studies
Risk factor associations in UK Biobank seem to be generalisable
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decision not to re­contact undecided potential 
participants.11 Presumably as a consequence, the 
project came in under budget and ahead of schedule.
Whereas such an approach is doubtless procedurally 
efficient, the long held view is that epidemiological 
studies need to achieve considerably higher response 
rates if their findings are to be credible.12 13 Debates 
about the effect of non­response on estimations 
of chronic disease determinants in UK Biobank—
its primary objective—and the wider necessity for 
representativeness have followed.14­23 Despite more 
favourable baseline risk factor levels and mortality 
rates in UK Biobank relative to studies achieving a 
greater response,24 its principal investigators have 
consistently maintained that, because the exposures 
of interest have sufficient variance and the study 
sample is large, the generalisability of associations 
between risk factors and health outcomes is assured.11 
25 26 Although findings from cohort studies sampled 
from highly select groups—Framingham residents 
and British civil servants,27 28 among many others29—
provide indirect support for this assertion, to our 
knowledge it has yet to be tested empirically.
To examine whether risk factor associations in UK 
Biobank are generalisable, in analyses of raw data 
from the study, we compared effect estimates for 
characteristics known to be linked to major causes 
of mortality against those from a pooling of data 
from nationally sampled cohort studies drawn from 
England and Scotland, all of which had a conventional 
response to their baseline surveys (mean 68%).30 
With UK Biobank data being deployed across a 
range of scientific disciplines, we also chose an array 
of mortality endpoints and exposures. Given the 
nature of our research question, our focus was not 
on discovery of risk factors; rather, our aim was to 
test risk factor­endpoint associations that are well 
established on the basis of strong observational 
and/or experimental evidence. We therefore related 
demographic, social, behavioural, and biomedical 
risk factors to cardiovascular disease,31 32 physical 
stature to cardiovascular disease and cancer,33­35 and 
educational attainment to suicide risk.36­39
Methods
We used individual level data from both UK Biobank,7 
a prospective cohort study, and a pooling of 18 other 
prospective cohort studies with identical core protocols: 
the Health Survey for England (HSE; 15 studies)40 and 
the Scottish Health Surveys (SHS; three studies)41 
(hereafter, HSE­SHS). The sampling and procedures 
of these studies have been well described.42 43 
In brief, baseline data collection in UK Biobank 
took place between 2006 and 2010 in 22 research 
assessment centres across the UK, resulting in a sample 
of 502 655 people aged 40 to 69 years (response rate 
5.5%).7 In HSE and SHS, a total of 193 842 people 
aged 16­102 years (mean response rate 68%; range 
58­93%30) participated in home based data collection 
between 1994 and 2008. For the purposes of this 
comparison, we restricted HSE­SHS data to the 89 895 
people (48 364 women) with a baseline age range that 
matched UK Biobank. Participants in both studies gave 
informed consent.
assessment of baseline characteristics
In both UK Biobank and HSE­SHS, the following data 
were self­reported using identical or near identical 
enquiries: diagnosis by a physician of chronic disease 
(diabetes, hypertension, cardiovascular disease); use 
of multivitamins, lipid lowering drugs, blood glucose 
lowering drugs, and antihypertensive drugs; educa­
tional attainment; cohabitation status; and cigarette 
smoking habit. Although physical activity and alcohol 
intake were collected using somewhat different 
questions, we were able to derive comparable binary 
categories (current non­drinker versus the rest; 
physically inactive versus the rest).
During medical examinations, waist and hip 
circumference, as well as height and weight, were 
measured directly using standard protocols. Elevated 
waist:hip ratio was denoted by values of 0.90 or 
greater for men and 0.85 or greater for women44; 
obesity was indicated by a body mass index of 30 or 
above.45 Forced expiratory volume in one second, 
a measure of pulmonary function, was quantified 
using spirometry with the best of three (UK Biobank) 
or five (HSE­SHS) technically satisfactory exhalations 
used in our analyses. In UK Biobank, seated systolic 
and diastolic blood pressure measurements were 
made twice using the Omron HEM­7015IT digital 
blood pressure monitor (Omron Healthcare)20 or, 
exceptionally, a manual sphygmomanometer (6652 
people); we used an average of the two readings. 
In HSE­SHS, three readings were taken using the 
Dinamap 8100 automated device,46 with a mean of the 
second and third values featuring in our analyses. We 
defined hypertension according to existing guidelines 
as systolic/diastolic blood pressure of 140/90 mm Hg 
or above, self­reported use of antihypertensive drugs, 
or both.47 Non­fasting venous blood was drawn in 
both studies.48 49 Assaying took place at dedicated 
central laboratories for C reactive protein, glycated 
haemoglobin, and total cholesterol and high density 
lipoprotein cholesterol.40 48
ascertainment of cause specific mortality
Participants in both studies were linked to mortality 
registries by using the procedures of the UK National 
Health Service Central Registry.50 We extracted 
underlying cause of death, coded according to ICD­
10 (international classification of disease, 10th 
revision), from death certificate data.50 We generated 
the following mortality outcomes: cardiovascular 
disease, all cancers combined, lung cancer, smoking 
attributable cancers, obesity attributable cancers, and 
suicide. The ICD codes denoting these causes of death 
are given in supplemental table 1.
statistical analyses
We calculated hazard ratios and accompanying 95% 
confidence intervals by using Cox regression models,51 
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adjusting effect estimates for age and sex. In these 
survival analyses, we censored individuals according to 
the date of death or the end of follow­up (14 February 
2011 in HSE, 31 December 2009 in SHS, 22 February 
2016 for UK Biobank), whichever came first. To quantify 
the difference between the hazard ratios in each of the 
two studies, we calculated a ratio of the hazard ratio 
as we have done in other contexts50 (HSE­SHS was the 
referent). We used Stata version 15 for all analyses.
Patient involvement
These analyses are based on existing data of typically 
healthy populations, and we were not involved in their 
recruitment. Thus, to our knowledge, no patients were 
explicitly engaged in designing the present research 
question or the outcome measures, nor were they 
involved in developing plans for recruitment, design, 
or implementation of the study. No patients were asked 
to advise on interpretation or writing up of results. 
Results from UK Biobank are routinely disseminated 
to study participants via the study website and social 
media outlets.
results
In table 1 (biomedical factors) and supplemental figure 
1 (demographic, social, and behavioural factors plus 
drug use), we compare the baseline characteristics 
of participants in UK Biobank against those in the 
compilation of 18 cohort studies. UK Biobank study 
members were less likely to have had a sub­university 
level education, to be living alone or unmarried, to be 
sedentary, to have existing cardiovascular disease, or 
to be taking drug treatments for raised blood glucose, 
although the reverse was seen for lipid lowering and 
antihypertensive drugs. In analyses restricted to study 
members not reporting the use of such therapies, we 
essentially observed no marked difference between 
studies members for total and high density lipoprotein 
cholesterol or for glycated haemoglobin. Whereas 
values for C reactive protein were lower in UK 
Biobank, both systolic and diastolic blood pressure 
were somewhat higher. Taken together, UK Biobank 
participants had a generally more favourable risk 
factor profile.
In UK Biobank, 14 288 deaths from all causes 
occurred during an average of 7.0 years of follow­
up in 499 701 people who consented to be linked 
to mortality registers. In the combined HSE­SHS 
databases, 10 years of mortality surveillance gave rise 
to 7861 deaths in 89 895 people with these consents. 
Of the five mortality categories examined in survival 
analyses, rates of cardiovascular disease, all cancers 
combined, and tobacco and obesity attributable 
cancers were markedly lower in UK Biobank, whereas 
the rate of suicide was higher (supplemental table 2).
In figure 1, for each study, we depict the association 
of known baseline demographic and behavioural risk 
factors with cardiovascular disease mortality. The 
expected direction of association was the same in both 
studies for the seven characteristics, whereby being 
male, being of higher age, being physically inactive, 
not drinking alcohol, not being married or cohabiting, 
being a current or former smoker, and not having a 
higher education degree were related to elevated rates 
of cardiovascular disease mortality. Some modest 
differences existed in the magnitude of these effects 
in four of the risk factors examined, such that hazard 
ratios were typically higher in UK Biobank. When we 
explored the links between biomedical factors and 
cardiovascular disease mortality (fig 2), all 10 of the 
biomarkers featured showed known associations 
with cardiovascular disease deaths in both studies. 
Although agreement between studies was again high, 
some heterogeneity was also apparent in the strength of 
these effects for higher levels of glycated haemoglobin, 
existing cardiovascular disease (stronger effects in 
UK Biobank than in HSE­SHS for both risk factors), 
and hypertension (the reverse). Taken together, a 
high degree of concordance existed for cardiovascular 
disease risk factor associations in UK Biobank and 
HSE­SHS.
Next, we examined the association of selected 
baseline factors with some non­cardiovascular disease 
mortality outcomes, including different presentations 
of cancer deaths and completed suicides (fig 3). 
Known risk factor associations were replicated across 
both studies. The magnitude of the association of 
cigarette smoking with lung cancer and malignancies 
table 1 | summary of baseline biomedical characteristics in uK biobank and Health survey for england and scottish 
Health surveys (Hse-sHs) cohort studies
characteristics uK biobank Hse-sHs
No of studies 1 18
No of participants (women) 502 655 (273 472) 89 895 (48 364)
Mean (SD) age, years 56.5 (8.10) 53.5 (8.6)
Mean (SD) FEV1, L 2.81 (0.80) 2.89 (0.89)
Mean (SD) total cholesterol, mmol/L 5.89 (1.07) 5.95 (1.14)
Median (IQR) high density lipoprotein cholesterol, mmol/L 1.43 (1.20-1.71) 1.40 (1.20-1.70)
Median (IQR) glycated haemoglobin, mmol/mol 35.0 (32.6-37.4) 36.6 (33.3-40.9)
Median (IQR) C reactive protein, mg/L 1.26 (0.63-2.49) 1.50 (0.70-3.10)
Mean (SD) systolic blood pressure, mm Hg 137.7 (19.3) 133.3 (18.4)
Mean (SD) diastolic blood pressure, mm Hg 81.6 (10.6) 76.6 (11.5)
FEV1=forced expiratory volume in one second; IQR=interquartile range; SD=standard deviation.
Sample size given is for study members with age data only and is lower for all other characteristics. Analyses for total cholesterol and high density 
lipoprotein exclude participants taking lipid lowering drugs; analyses for glycated haemoglobin exclude people with self-reported diabetes and those 
taking blood glucose lowering drugs; analyses for C reactive protein exclude people with values >10 mg/L; and analyses for blood pressure exclude 
people taking antihypertensive drugs.
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causatively linked to tobacco intake were weaker for 
UK Biobank, whereas obesity and cancers attributed 
to it yielded similar effects in each study. Hazard ratios 
were also essentially the same for lower educational 
attainment and suicide, although statistical power 
was modest in these analyses, particularly for HSE­
SHS, as evidenced by the wide confidence intervals. 
Physical stature showed the predicted opposing 
and shallow gradients for cardiovascular disease 
(negative) and cancer (positive); again, effect sizes 
were very similar in both studies.
Given well known secular changes in risk factors 
levels, as evidenced by repeat cross sectional 
surveys,52 we used sensitivity analyses to explore 
the effect of having the same calendar period (2006­
08) for recruitment of participants in HSE and UK 
Biobank (supplemental figure 2), and in another 
set of analyses we additionally aligned mortality 
surveillance by right censoring in UK Biobank 
(follow­up to 14 February 2011) (supplemental 
figure 3). Owing to a rarity of events, these analyses 
were restricted to death from cardiovascular disease. 
Risk factor associations were essentially the same 
as those apparent in the main analyses, the only 
exception being obesity. We also found that results 
held in sex specific analyses for demographic and 
behavioural characteristics (supplemental figure 4) 
and biomarkers (supplemental figure 5). Lastly, given 
that, as described, the self reported use of drugs for 
lowering blood pressure and lipids was higher in 
members of UK Biobank relative to our comparator 
cohorts, we tested whether this was also evident for 
other health seeking behaviours such as vitamin and 
mineral supplementation. The prevalence of such 
use was counter to expectations, being lower in UK 
Biobank (21.8%) than in HSE­SHS (33.1%).
discussion
In a comparison of findings between UK Biobank and 
18 studies from the HSE­SHS consortium, we found 
close agreement for a series of well established risk 
factors for cause specific mortality. These concordant 
results were apparent despite the response rate in UK 
Biobank being an order of magnitude lower than in the 
comparator cohorts and that study having a generally 
more favourable prevalence of sociodemographic, 
behavioural, and health related characteristics at 
baseline and lower rates of cause specific mortality 
during follow­up, as shown here and elsewhere.24
Findings from other studies
The only other analyses of risk factor relations in 
UK Biobank versus those in comparator studies of 
which we are aware are those for cardiometabolic 
Male sex
  UK Biobank
  HSE-SHS
Physically inactive
  UK Biobank
  HSE-SHS
Current non-drinker
  UK Biobank
  HSE-SHS
Not married/cohabiting
  UK Biobank
  HSE-SHS
Ever cigarette smoker
  UK Biobank
  HSE-SHS
Age (per 5 year increase)
  UK Biobank
  HSE-SHS
Less than university education
  UK Biobank
  HSE-SHS
1.70 (1.48 to 1.96)
1.46 (1.22 to 1.75)
1.22 (1.01 to 1.48)
1.17 (1.02 to 1.35)
1.02 (0.88 to 1.19)
0.91 (0.87 to 0.95)
0.83 (0.69 to 1.01)
Risk factor
and study
0.25 2 3 41 5
Hazard ratio
(95% CI)
RHR
(95% CI)
3.78 (3.42 to 4.17)
2.22 (2.00 to 2.46)
3.40 (3.04 to 3.80)
2.33 (2.02 to 2.68)
1.94 (1.72 to 2.20)
1.59 (1.38 to 1.83)
2.22 (2.02 to 2.43)
1.89 (1.71 to 2.10)
2.04 (1.87 to 2.24)
1.99 (1.78 to 2.23)
1.65 (1.59 to 1.70)
1.81 (1.75 to 1.88)
1.59 (1.44 to 1.77)
1.91 (1.59 to 2.31)
Hazard ratio
(95% CI)
502 655
89 895
495 497
56 703
501 152
89 845
455 597
89 837
499 701
89 766
502 655
89 895
492 513
89 844
No
2251
1596
2162
933
2240
1592
2038
1588
2224
1592
2251
1596
2167
1593
Deaths
Fig 1 | association of baseline demographic and behavioural characteristics with cardiovascular disease mortality 
in uK biobank and Health survey for england/scottish Health surveys (Hse-sHs) cohort studies. Hazard ratios 
are adjusted for age and sex, with the exception of individual effects for age and sex which are mutually adjusted. 
squares indicate hazard ratios and error bars denote 95% ci for relation of each characteristic with risk of death 
outcome. ratio of hazard ratios (rHr) summarises between study differences (Hse-sHs is reference group) for effect 
estimates for each outcome
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multimorbidity and venous thromboembolism in the 
Emerging Risk Factors Collaboration, a pooling of data 
from up to 91 cohort studies.53 54 The goal of those 
papers, however, was discovery of risk factors rather 
than testing well established associations between risk 
factors and chronic disease. Blood based biomarkers 
in UK Biobank were also not available at the time of 
these analyses and, in the report featuring venous 
thromboembolism as the endpoint of interest,54 
inter­study comparison was hampered by differing 
approaches to disease ascertainment.
As described, UK Biobank principal investigators, 
while acknowledging that their study has little value 
in describing the prevalence of a risk factor or rates 
of mortality—never stated objectives—have attempted 
to minimise unease around the investigation of 
chronic disease aetiology—its primary purpose—by 
arguing that generalisable associations with risk 
factors can be obtained in non­representative samples 
provided sufficiently large numbers of people with a 
range of exposures are included.11 25 26 They cite the 
circumstantial evidence of cohort studies drawing 
on selected populations that have markedly higher 
response rates than UK Biobank—Framingham resi­
dents,27 British physicians,55 US nurses56—all of 
which produced results that have subsequently been 
shown to be transportable to general population based 
studies and have contributed much to the prevention of 
cardiovascular disease and selected cancers. Similarly, 
our findings mirror those from analyses in which we 
have compared risk factors for coronary heart disease 
in another highly select group, a cohort of British 
HbA1c (per doubling in mmol/mol)
  UK Biobank
  HSE-SHS
Self-reported CVD
  UK Biobank
  HSE-SHS
Obesity
  UK Biobank
  HSE-SHS
Elevated waist:hip ratio
  UK Biobank
  HSE-SHS
Self-reported diabetes
  UK Biobank
  HSE-SHS
FEV1 (per 0.5 L/s increase)
  UK Biobank
  HSE-SHS
Total cholesterol (per 1 mmol/L increase)
  UK Biobank
  HSE-SHS
C reactive protein (per doubling in mg/L)
  UK Biobank
  HSE-SHS
HDL cholesterol (per doubling in mmol/L)
  UK Biobank
  HSE-SHS
Hypertension
  UK Biobank
  HSE-SHS
1.95 (1.22 to 3.12)
1.89 (1.69 to 2.11)
1.14 (0.99 to 1.32)
1.12 (0.86 to 1.47)
1.09 (0.91 to 1.31)
1.02 (0.91 to 1.15)
0.98 (0.89 to 1.08)
0.95 (0.85 to 1.07)
0.91 (0.66 to 1.26)
0.74 (0.62 to 0.89)
Risk factor
and study
0.25 2 3 41 5
Hazard ratio
(95% CI)
RHR
(95% CI)
3.86 (3.18 to 4.69)
1.98 (1.29 to 3.02)
4.92 (4.50 to 5.39)
2.61 (2.35 to 2.90)
1.68 (1.55 to 1.83)
1.47 (1.31 to 1.64)
1.88 (1.69 to 2.09)
1.67 (1.31 to 2.14)
3.73 (3.38 to 4.12)
3.43 (2.96 to 3.96)
0.69 (0.67 to 0.72)
0.68 (0.64 to 0.72)
1.01 (0.96 to 1.07)
1.04 (0.96 to 1.12)
1.30 (1.25 to 1.35)
1.36 (1.23 to 1.52)
0.51 (0.42 to 0.62)
0.56 (0.43 to 0.72)
1.89 (1.69 to 2.11)
2.56 (2.20 to 2.98)
Hazard ratio
(95% CI)
442 130
20 895
500 431
89 871
499 589
82 656
502 655
56 513
500 038
89 871
453 836
26 742
387 923
30 946
449 141
19 475
354 782
25 951
494 047
57 116
No
1593
218
2240
1596
2204
1411
2251
875
2233
1596
1765
629
1074
477
1859
220
995
323
2179
1002
Deaths
Fig 2 | association of baseline biomedical characteristics with cardiovascular disease (cvD) mortality in uK biobank and Health survey for england/
scottish Health surveys (Hse-sHs) cohort studies. Hazard ratios are adjusted for age and sex. squares indicate hazard ratios and error bars denote 
95% ci for relation of each characteristic with risk of death outcome. ratio of hazard ratios (rHr) summarises between study differences (Hse-
sHs is reference group) for effect estimates for each outcome. Distributions of glycated haemoglobin (Hba1c), c reactive protein, and high density 
lipoprotein (HDl) cholesterol were skewed, so they were log2 transformed and effect estimates reflect doubling for each biomarker. elevated 
waist:hip ratio was denoted by ≥0.90 for men and ≥0.85 for women; obesity was indicated by body mass index ≥30. Fev1=forced expiratory volume in 
one second
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civil servants (the Whitehall II prospective cohort 
study), with those from a cohort based on the general 
population (the British Regional Heart Study).57 In 
those analyses, we also found near identical risk factor 
relations across studies.
limitations of study
Our work inevitably has some shortcomings. Firstly, 
whereas UK Biobank includes people from the 
contiguous countries that comprise the UK, the 
comparator studies included no data from Wales. We 
have no reason to believe that the absence of these 
data would affect our results, however. Secondly, 
whereas core elements of data collection in the HSE­
SHS consortium were essentially constant across 
studies, scientific themes for data collection differed 
from year to year.40 As such, selected biomedical data 
were not collected in all survey years and the analytical 
sample size was diminished as a result. Thirdly, for 
two variables—physical activity and alcohol intake—
baseline data were not directly comparable between 
studies, although we were able to harmonise data 
into binary groups. These represent two of 23 risk 
factor­outcome combinations, however, which means 
that exclusion of these data would have no effect on 
our overall conclusions of high agreement between 
studies. Fourthly, the mode of data collection differed 
between studies—data collection in UK Biobank took 
place in designated research centres, whereas it was 
home based in HSE­SHS—although we see no strong 
justification for this affecting our results. Fifthly, in 
the main analyses, the endpoint of the interest was 
cardiovascular disease mortality, which is an amalgam 
of both incidence of the condition and survival with 
it. This raises the question of whether risk factor 
effects differ for incidence, which is temporally closer 
to assessment of exposure than is death. However, 
comparison of risk factors for coronary heart disease 
and stroke, as ascertained from mortality records 
and hospital admissions (incidence), have shown 
no evidence of differential associations.58 59 Lastly, 
although blood samples have been frozen in HSE­SHS, 
so offering the potential for later genome sequencing, 
comparison with genetic risk prediction of chronic 
disease in UK Biobank is currently not possible. 
From a purely gene­outcome association perspective, 
however, with genetic variants being unlikely to be 
associated with either self­selection into the study or 
confounding factors, UK Biobank is likely to produce 
generalisable estimates of genetic risk.19
conclusions
Despite a low response rate, risk factor associations 
in UK Biobank seem to be generalisable. This suggests 
Ever cigarette smoker
  Lung cancer
    UK Biobank
    HSE-SHS
  Tobacco related cancer
    UK Biobank
    HSE-SHS
Obesity
  Obesity related cancer
    UK Biobank
    HSE-SHS
Less than university education
  Suicide
    UK Biobank
    HSE-SHS
Physical stature (per 5 cm increase)
  Cancer
    UK Biobank
    HSE-SHS
  Cardiovascular disease
    UK Biobank
    HSE-SHS
0.57 (0.40 to 0.81)
0.79 (0.69 to 0.91)
1.06 (0.91 to 1.23)
1.07 (0.42 to 2.74)
1.00 (0.97 to 1.03)
1.02 (0.97 to 1.08)
Risk factor,
outcome and study
0.5 2 5 15101 20
Hazard ratio
(95% CI)
RHR
(95% CI)
7.60 (6.50 to 8.88)
13.42 (9.71 to 18.54)
2.44 (2.29 to 2.61)
3.08 (2.73 to 3.48)
1.24 (1.15 to 1.33)
1.17 (1.02 to 1.34)
1.29 (0.95 to 1.74)
1.20 (0.49 to 2.92)
1.02 (1.01 to 1.04)
1.02 (0.99 to 1.05)
0.86 (0.83 to 0.89)
0.84 (0.81 to 0.88)
Hazard ratio
(95% CI)
499 701
89 766 
499 701
89 766
499 589
82 656
492 513
89 844
500 115
85 300
500 115
85 300
No
1493
737
4165
1707
3270
1030
205
34
8237
2789
2217
1451
Deaths
Fig 3 | association of selected baseline characteristics with cause specific mortality in uK biobank and Health survey for england/scottish Health 
surveys (Hse-sHs) cohort studies. Hazard ratios are adjusted for age and sex. squares indicate hazard ratios and error bars denote 95% ci for 
relation of each characteristic with risk of death outcome. ratio of hazard ratios (rHr) summarises between study differences (Hse-sHs is reference 
group) for effect estimates for each outcome
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that the cost and time saving features of recruitment of 
study members did not affect aetiological utility.
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